Novel Formazan Derivative: Synthesis, Characterization, Anti-breast Cancer and Antioxidant Investigation
DOI:
https://doi.org/10.36329/jkcm/2022/v2.i9.13305Keywords:
Formazan, breast cancer, antioxidant activityAbstract
New formazan (FOZ) derivative was synthesized and evaluated as an anti-breast cancer and antioxidant agent. Chemical structure of FOZ was proved by CHN, FT-IR, 1H-NMR and Mass techniques. The anti-proliferative activity of FOZ was estimated toward breast cancer cells. The synthesized compound displayed significant anti-breast cancer activity towered MCF-7 cells. The MTT examination demonstrated that 16 µg/ml of FOZ and doxorubicin (Dox) as a standard drug suppressed cell growth by 83.33% and 92.66%, respectively after 48hrs. The formazan antioxidant activity was estimated in vitro at various concentrations (25-400ug/ml) and the outcomes showed that 400 μg/ml of FOZ was more efficient compared to ascorbic acid
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Journal of Kufa for Chemical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
Open-access Statement
The journal « Journal Of Kufa For Chemical Sciences» provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. Full-text access to scientific articles of the journal is presented on the official website in the Archives section.
This is in accordance with the BOAI definition of open access. The licensing policy is compatible with the overwhelming majority of open access and archiving policies.
The journal «Journal Of Kufa For Chemical Sciences» is an open access journal, which means all its content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.The journal is licensed by Creative Commons Attribution International( CC Attribution 4.0) .
